iPLEDGE, the required safety program for isotretinoin, now lets your teen's prescriber allow home pregnancy tests during and after treatment. Testing before starting treatment must still happen in a medical setting. The FDA approved the changes on February 9, 2026 to reduce burden while keeping safeguards against fetal exposure. They took effect August 9, 2026, according to Drugs.com coverage of the FDA approval notice.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Register through FDA’s official page — Use this page to review requirements and register directly.
- Read the official guidance from Ncpa — Use this primary source to verify the official guidance.
Table of Contents
- What Changed in August 2026?
- Which Tests Must Stay in the Clinic?
- What Does Monthly Compliance Still Require?
- How Should Parents Plan Visits and Home Tests?
What Changed in August 2026?
Prescribers may now allow patients who can become pregnant to complete required tests at home during and after treatment. The tests no longer have to occur only in a CLIA-certified laboratory, which means a certified medical lab, according to the National Community Pharmacists Association in its February update.
The FDA also ended the 19-day lockout after a missed 7-day prescription pickup window. A repeat pregnancy test can now be done right away with no waiting period, according to Healio dermatology news in its February report.
Which Tests Must Stay in the Clinic?
Pre-treatment pregnancy testing must still occur in a medical setting such as the prescriber office or laboratory. Dermatology Advisor reporting on FDA requirements states this rule for testing before starting isotretinoin therapy.
The same in-person rule applies to any repeat test needed to start treatment. Home testing is not automatic and needs prescriber permission plus ordering, review, and documentation, with pharmacy clearance from iPLEDGE before each dispense.
What Does Monthly Compliance Still Require?
The rules affect patients age 12 and older with severe nodular acne, hard deep lumps, unresponsive to other treatments, who can become pregnant. The FDA iPLEDGE fact sheet states they must enroll and use two contraception forms or abstinence starting 1 month before, during, and for 1 month after treatment, plus monthly tests. Parents can track four ongoing requirements: Missing a pickup no longer triggers a long lockout, but the pharmacy still cannot dispense without that clearance.
- iPLEDGE enrollment stays active for the teen
- two birth control methods or abstinence without gaps across the full time window
- required pregnancy test completed on schedule each month
- pharmacy iPLEDGE clearance obtained before each dispense
How Should Parents Plan Visits and Home Tests?
Monthly teen monitoring may be done by home test or telemedicine if the dermatologist authorizes it. The Medaptly summary of the 2026 changes describes this option for families managing follow-up care.
Parents must still plan in-person visits for pre-treatment tests and for any repeat test to start treatment. Ask the dermatologist at the first visit whether home tests will be allowed and how results should be sent.
You Might Also Like
- Pretreatment Pregnancy Testing Under iPLEDGE in 2026: Timeline and Transition Questions for Parents of Teens With Severe Acne
- Pediatric Acne and Rosacea at the 2026 AAD Annual Meeting: What the Update Means for Parents of Teens With Acne
- Pediatric Acne and Rosacea at the 2026 AAD Annual Meeting: Questions Parents of Teens With Acne Can Ask a Dermatologist